Tranzyme Pharma’s DIGEST Trial Stopped for Futility After Interim Analysis of the Phase 2b Results

[at noodls] – RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2012 (GLOBE NEWSWIRE) — Tranzyme Pharma (Nasdaq:TZYM) today announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in … more

View todays social media effects on OCRX

View the latest stocks trending across Twitter. Click to view dashboard

See who Ocera is hiring next, click here to view